Drugs / UTRELOXASTAT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05349721 | May 2022 → Sep 2024 | amyotrophic lateral sclerosis | PTC Therapeutics | Terminated | Missed primary |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-26 | PTC Therapeutics | PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients ptcbio.com ↗ |
| 2020-07-08 | PTC Therapeutics | PTC Therapeutics Announces First Patient Dosed in Phase 1 Trial for PTC857 ptcbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UTRELOXASTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314565 ↗ |
| Known as | PTC857 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05349721 ↗ |
| Modality | Small molecule | — CHEMBL5314565 ↗ |